- Home
- PACB vs IMMP Comparison
PACB vs IMMP Comparison
Compare PACB & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PACB
- IMMP
- Stock Information
- Founded
- PACB 2000
- IMMP 1987
- Country
- PACB United States
- IMMP Australia
- Employees
- PACB N/A
- IMMP N/A
- Industry
- PACB Biotechnology: Laboratory Analytical Instruments
- IMMP Biotechnology: Pharmaceutical Preparations
- Sector
- PACB Industrials
- IMMP Health Care
- Exchange
- PACB Nasdaq
- IMMP Nasdaq
- Market Cap
- PACB 364.2M
- IMMP 304.0M
- IPO Year
- PACB 2010
- IMMP N/A
- Fundamental
- Price
- PACB $1.31
- IMMP $1.70
- Analyst Decision
- PACB Buy
- IMMP Buy
- Analyst Count
- PACB 13
- IMMP 2
- Target Price
- PACB $2.79
- IMMP $8.50
- AVG Volume (30 Days)
- PACB 14.1M
- IMMP 81.6K
- Earning Date
- PACB 02-13-2025
- IMMP 03-18-2025
- Dividend Yield
- PACB N/A
- IMMP N/A
- EPS Growth
- PACB N/A
- IMMP N/A
- EPS
- PACB N/A
- IMMP N/A
- Revenue
- PACB $154,014,000.00
- IMMP $3,019,249.00
- Revenue This Year
- PACB $7.12
- IMMP N/A
- Revenue Next Year
- PACB $26.83
- IMMP $20.28
- P/E Ratio
- PACB N/A
- IMMP N/A
- Revenue Growth
- PACB N/A
- IMMP 24.11
- 52 Week Low
- PACB $1.16
- IMMP $1.66
- 52 Week High
- PACB $4.42
- IMMP $3.34
- Technical
- Relative Strength Index (RSI)
- PACB 40.33
- IMMP 31.71
- Support Level
- PACB $1.27
- IMMP $1.84
- Resistance Level
- PACB $1.47
- IMMP $1.88
- Average True Range (ATR)
- PACB 0.15
- IMMP 0.10
- MACD
- PACB -0.01
- IMMP -0.02
- Stochastic Oscillator
- PACB 6.78
- IMMP 0.00
About PACB Pacific Biosciences of California Inc.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.
About IMMP Immutep Limited
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.